AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Koshinski Asset Management Inc.

Koshinski Asset Management Inc. lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 6,611 shares of the company’s stock after selling 220 shares during the quarter. Koshinski Asset Management Inc.’s holdings in AstraZeneca were worth $515,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Bruce G. Allen Investments LLC increased its position in shares of AstraZeneca by 19.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock valued at $67,000 after purchasing an additional 138 shares during the period. Carnegie Investment Counsel grew its stake in AstraZeneca by 0.8% during the 2nd quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock valued at $1,347,000 after acquiring an additional 138 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in shares of AstraZeneca by 40.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares in the last quarter. Sunpointe LLC grew its position in AstraZeneca by 4.5% during the second quarter. Sunpointe LLC now owns 3,419 shares of the company’s stock valued at $267,000 after purchasing an additional 147 shares in the last quarter. Finally, Argonautica Private Wealth Management Inc. increased its stake in AstraZeneca by 4.0% in the 2nd quarter. Argonautica Private Wealth Management Inc. now owns 3,874 shares of the company’s stock valued at $302,000 after buying an additional 149 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. TD Cowen boosted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Barclays upgraded AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Finally, Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Trading Up 1.0 %

Shares of NASDAQ:AZN opened at $78.10 on Tuesday. The stock’s 50-day moving average is $81.34 and its 200-day moving average is $77.97. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a market cap of $242.15 billion, a P/E ratio of 38.28, a P/E/G ratio of 1.42 and a beta of 0.46. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.99 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. The company had revenue of $12.45 billion during the quarter, compared to analyst estimates of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.08 earnings per share. Equities research analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current year.

AstraZeneca Cuts Dividend

The company also recently announced a Semi-Annual dividend, which was paid on Monday, September 9th. Investors of record on Friday, August 9th were given a dividend of $0.49 per share. This represents a yield of 1.8%. The ex-dividend date of this dividend was Friday, August 9th. AstraZeneca’s dividend payout ratio (DPR) is presently 48.04%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.